HEALTHCARE COSTS IN WOMEN WITH HR+/HER2- METASTATIC BREAST CANCER TREATED WITH CDK4/6 INHIBITORS

Author(s)

Burne R1, Balu S2, Guerin A1, Liang Y1, Schloessmann R3, Bungay R1, Paul ML2
1Analysis Group, Inc., Montreal, QC, Canada, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 3Analysis Group, Inc., Chicago, IL, USA

OBJECTIVES: To describe and compare healthcare costs in patients treated with CDK4/6 inhibitors in real-world clinical practice.

METHODS: Adult women with HR+/HER2- advanced or mBC who initiated treatment with a CDK4/6 inhibitor (palbociclib, ribociclib, abemaciclib) were identified from IBM MarketScan Data (Q1 2000 - Q3 2018), a large US commercial claims database. Previously published claims-based algorithms were used to identify HR+/HER2- and menopausal status. The index date was defined as date of CDK4/6 initiation. Total healthcare costs, measured from a payers' perspective, included medical and pharmacy costs reported per-patient-per-month (PPPM). Inpatient and outpatient costs were also separately described.

RESULTS: 4,320 pts were included: 100 patients initiated abemaciclib as first CDK4/6 (median age: 59; 92% postmenopausal); 4,118 palbociclib (median age: 60; 92% postmenopausal); and 102 ribociclib (median age: 58.5; 79.4% postmenopausal). At baseline, median Charlson Comorbidity Index was 6.0 in all cohorts (mean: 6.8 in abemaciclib and palbociclib cohorts, 6.7 in ribociclib cohort). In the abemaciclib, palbociclib, and ribociclib cohorts respectively, 30%, 31%, and 40% received treatment in first-line therapy, 22%, 24%, and 23% second-line, and 33%, 29% and 24% third-line or later. Mean total healthcare costs PPPM while on therapy were $25,920, $19,976, and $19,175 in the abemaciclib, palbociclib, and ribociclib cohorts, respectively. Mean total inpatient costs PPPM were $3,748, $1,926, $1,871, and outpatient costs were $8,298, $5,727, $4,578 in the abemaciclib, palbociclib, and ribociclib cohorts, respectively. Mean total pharmacy costs were $13,542, $12,048, and $12,040 in the abemaciclib, palbociclib, and ribociclib cohorts, respectively.

CONCLUSIONS: Total healthcare costs PPPM while on treatment appeared to be highest in the abemaciclib cohort, while ribociclib and palbociclib cohorts tend to have similar total healthcare costs.

Conference/Value in Health Info

2020-05, ISPOR 2020, Orlando, FL, USA

Value in Health, Volume 23, Issue 5, S1 (May 2020)

Code

PCN120

Topic

Economic Evaluation

Disease

Oncology

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×